Physician profile
Susan E Schoeneman
NPI 1386991636
$6,440.85
in general payments reported to CMS, 2019-2025
50 companies · $833 in 2025
The $833 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,250 · 2022: $1,647 · 2023: $1,623 · 2024: $1,087 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.48 |
| Education | $402.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $717.20 | 2021-2025 | Padcev, Xospata, Vyloy |
| Daiichi Sankyo INC. | $709.72 | 2021-2025 | Enhertu, Injectafer |
| Seagen INC. | $433.74 | 2021-2023 | Padcev, Tukysa, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $383.68 | 2021-2025 | Opdivo, Krazati, Eliquis |
| Glaxosmithkline, LLC. | $312.68 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $277.57 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Amgen INC. | $264.49 | 2021-2023 | Vectibix, Nplate, Xgeva |
| Novartis Pharmaceuticals Corporation | $264.27 | 2022-2025 | |
| Abbvie INC. | $245.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $211.93 | 2021-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $199.76 | 2021-2025 | Rybrevant, Darzalex |
| Pfizer INC. | $192.33 | 2021-2025 | |
| Tersera Therapeutics LLC | $189.39 | 2021-2025 | Zoladex |
| Genzyme Corporation | $182.46 | 2021-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $182.10 | 2021-2023 | Imbruvica, Epkinly |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $131.55 | 2021-2025 | Enhertu, Tagrisso |
| Eisai INC. | $96.00 | 2023-2024 | |
| Mirati Therapeutics, INC. | $89.93 | 2023-2024 | Krazati |
| Adaptive Biotechnologies Corporation | $81.54 | 2022-2024 | Clonoseq |
| Karyopharm Therapeutics INC. | $75.33 | 2022-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $75.01 | 2021-2025 | |
| Coherus Oncology, INC. | $74.01 | 2021-2023 | |
| Emd Serono, INC. | $72.22 | 2022-2024 | Bavencio |
| Servier Pharmaceuticals LLC | $70.63 | 2022-2024 | |
| Myriad Genetic Laboratories, INC. | $69.41 | 2023 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $66.69 | 2022-2023 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $63.36 | 2022-2024 | Libtayo |
| Morphosys, US INC. | $60.32 | 2021-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $51.59 | 2023 | Besremi |
| Celgene Corporation | $50.13 | 2022-2024 | Reblozyl, Pomalyst |
| Stemline Therapeutics INC. | $47.64 | 2025 | Orserdu |
| Foundation Medicine, INC. | $43.03 | 2021-2022 | |
| Gilead Sciences, INC. | $40.84 | 2021-2022 | |
| Genentech USA, INC. | $37.21 | 2021-2024 | Perjeta, Phesgo |
| Rigel Pharmaceuticals, INC. | $33.81 | 2021-2025 | Gavreto, Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $32.58 | 2022-2023 | |
| Clovis Oncology, INC. | $32.41 | 2021 | |
| Array Biopharma INC | $31.14 | 2021 | |
| G1 Therapeutics, INC. | $31.05 | 2022-2023 | Cosela |
| Travere Therapeutics, INC. | $25.18 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $23.98 | 2023 | Pyrukynd |
| Phathom Pharmaceuticals, INC. | $23.36 | 2024 | Voquezna |
| Immunogen, INC. | $23.17 | 2023 | Elahere |
| Lilly USA, LLC | $21.66 | 2023 | Retevmo, Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $20.90 | 2023 | Ninlaro |
| Puma Biotechnology, INC. | $17.71 | 2021 | |
| Springworks Therapeutics, INC. | $17.41 | 2025 | Ogsiveo |
| Octapharma USA, INC. | $15.53 | 2022 | |
| Sirtex Medical INC | $13.94 | 2022 | |
| Cti Biopharma Corp. | $13.41 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Schoeneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.